Skip to main content
Erschienen in: Endocrine 2/2014

01.11.2014 | Original Article

Detection of serum p53 antibodies from Chinese patients with papillary thyroid carcinoma using phage-SP-ELISA: correlation with clinical parameters

verfasst von: Pengtao Pan, Xiaoyi Han, Fangqian Li, Qingfeng Fu, Xiang Gao, Hui Sun, Li Wang

Erschienen in: Endocrine | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The goal of the present study was to investigate whether p53 antibodies (Abs) could be a relevant marker for papillary thyroid carcinoma (PTC). Three types of enzyme-linked immunosorbent assay (ELISA) methods were developed for the detection of p53 Abs, including p53-ELISA, phage-SS-ELISA, and phage-SP-ELISA. A total of 304 patients, including 117 cases with thyroid adenoma and 187 PTC patients, were enrolled in this study. Expression of p53 protein and mutation in BRAF gene were evaluated in paraffin-embedded tissue from 44 patients with PTC, in order to elucidate their correlations with the presence of p53 Abs. Compared with p53-ELISA and phage-SS-ELISA, phage-SP-ELISA presented the highest detection efficiency of p53 Abs in patients with PTC, and a combination of these three ELISA systems could make the detection of p53 Abs more sensitive than using each of the individual ELISA methods. Furthermore, p53 Abs was positively associated with clinical stage (P = 0.044), node metastasis (P = 0.010), and p53 protein accumulation (P = 0.019). These results indicate that serum p53 Abs could be a useful marker for PTC.
Literatur
1.
Zurück zum Zitat L. Davies, H.G. Welch, Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295, 2164–2167 (2006)PubMedCrossRef L. Davies, H.G. Welch, Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295, 2164–2167 (2006)PubMedCrossRef
2.
Zurück zum Zitat S.A. Hundahl, I.D. Fleming, A.M. Fremgen, H.R. Menck, A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83, 2638–2648 (1998)PubMedCrossRef S.A. Hundahl, I.D. Fleming, A.M. Fremgen, H.R. Menck, A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83, 2638–2648 (1998)PubMedCrossRef
3.
Zurück zum Zitat D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, S.I. Sherman, R.M. Tuttle, American Thyroid Association Guidelines Taskforce, Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16, 109–142 (2006)PubMedCrossRef D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, S.I. Sherman, R.M. Tuttle, American Thyroid Association Guidelines Taskforce, Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16, 109–142 (2006)PubMedCrossRef
4.
Zurück zum Zitat T. Kunavisarut, Diagnostic biomarkers of differentiated thyroid cancer. Endocrine 44, 616–622 (2013)PubMedCrossRef T. Kunavisarut, Diagnostic biomarkers of differentiated thyroid cancer. Endocrine 44, 616–622 (2013)PubMedCrossRef
5.
Zurück zum Zitat Y. Cohen, M. Xing, E. Mambo, Z. Guo, G. Wu, B. Trink, U. Beller, W.H. Westra, P.W. Ladenson, D. Sidransky, BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst. 95, 625–627 (2003)PubMedCrossRef Y. Cohen, M. Xing, E. Mambo, Z. Guo, G. Wu, B. Trink, U. Beller, W.H. Westra, P.W. Ladenson, D. Sidransky, BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst. 95, 625–627 (2003)PubMedCrossRef
6.
Zurück zum Zitat M.N. Nikiforova, Y.E. Nikiforov, Molecular diagnostics and predictors in thyroid cancer. Thyroid 19, 1351–1361 (2009)PubMedCrossRef M.N. Nikiforova, Y.E. Nikiforov, Molecular diagnostics and predictors in thyroid cancer. Thyroid 19, 1351–1361 (2009)PubMedCrossRef
7.
Zurück zum Zitat M. Xing, D. Clark, H. Guan, M. Ji, A. Dackiw, K.A. Carson, M. Kim, A. Tufaro, P. Ladenson, M. Zeiger, R. Tufano, BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J. Clin. Oncol. 27, 2977–2982 (2009)PubMedCrossRefPubMedCentral M. Xing, D. Clark, H. Guan, M. Ji, A. Dackiw, K.A. Carson, M. Kim, A. Tufaro, P. Ladenson, M. Zeiger, R. Tufano, BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J. Clin. Oncol. 27, 2977–2982 (2009)PubMedCrossRefPubMedCentral
8.
Zurück zum Zitat L. Crawford, D. Pim, R. Bulbrook, Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer 30, 403–408 (1982)PubMedCrossRef L. Crawford, D. Pim, R. Bulbrook, Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer 30, 403–408 (1982)PubMedCrossRef
9.
Zurück zum Zitat T. Soussi, p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 60, 1777–1788 (2000)PubMed T. Soussi, p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 60, 1777–1788 (2000)PubMed
10.
Zurück zum Zitat V. Goodell, L.G. Salazar, N. Urban, C.W. Drescher, H. Gray, R.E. Swensen, M.W. McIntosh, M.L. Disis, Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J. Clin. Oncol. 24, 762–768 (2006)PubMedCrossRef V. Goodell, L.G. Salazar, N. Urban, C.W. Drescher, H. Gray, R.E. Swensen, M.W. McIntosh, M.L. Disis, Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J. Clin. Oncol. 24, 762–768 (2006)PubMedCrossRef
11.
Zurück zum Zitat C. Chapman, A. Murray, J. Chakrabarti, A. Thorpe, C. Woolston, U. Sahin, A. Barnes, J. Robertson, Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann. Oncol. 18, 868–873 (2007)PubMedCrossRef C. Chapman, A. Murray, J. Chakrabarti, A. Thorpe, C. Woolston, U. Sahin, A. Barnes, J. Robertson, Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann. Oncol. 18, 868–873 (2007)PubMedCrossRef
12.
Zurück zum Zitat M. Lechpammer, J. Lukač, S. Lechpammer, D. Kovačević, M. Loda, Z. Kusić, Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int. J. Colorectal Dis. 19, 114–120 (2004)PubMedCrossRef M. Lechpammer, J. Lukač, S. Lechpammer, D. Kovačević, M. Loda, Z. Kusić, Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int. J. Colorectal Dis. 19, 114–120 (2004)PubMedCrossRef
13.
Zurück zum Zitat R. Ralhan, S. Arora, T.K. Chattopadhyay, N.K. Shukla, M. Mathur, Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int. J. Cancer 85, 791–795 (2000)PubMedCrossRef R. Ralhan, S. Arora, T.K. Chattopadhyay, N.K. Shukla, M. Mathur, Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int. J. Cancer 85, 791–795 (2000)PubMedCrossRef
14.
Zurück zum Zitat R. Tang, M.C. Ko, J.Y. Wang, C.R. Changchien, H.H. Chen, J.S. Chen, K.C. Hsu, J.M. Chiang, L.L. Hsieh, Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int. J. Cancer 94, 859–863 (2001)PubMedCrossRef R. Tang, M.C. Ko, J.Y. Wang, C.R. Changchien, H.H. Chen, J.S. Chen, K.C. Hsu, J.M. Chiang, L.L. Hsieh, Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int. J. Cancer 94, 859–863 (2001)PubMedCrossRef
15.
Zurück zum Zitat P. Lenner, F. Wiklund, S. Emdin, C. Arnerlöv, C. Eklund, G. Hallmans, H. Zentgraf, J. Dillner, Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Br. J. Cancer 79, 927–932 (1999)PubMedCrossRefPubMedCentral P. Lenner, F. Wiklund, S. Emdin, C. Arnerlöv, C. Eklund, G. Hallmans, H. Zentgraf, J. Dillner, Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Br. J. Cancer 79, 927–932 (1999)PubMedCrossRefPubMedCentral
16.
Zurück zum Zitat J. Bourhis, R. Lubin, B. Roche, S. Koscielny, J. Bosq, I. Dubois, M. Talbot, P. Marandas, G. Schwaab, P. Wibault, B. Luboinski, F. Eschwege, T. Soussi, Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J. Natl. Cancer Inst. 88, 1228–1233 (1996)PubMedCrossRef J. Bourhis, R. Lubin, B. Roche, S. Koscielny, J. Bosq, I. Dubois, M. Talbot, P. Marandas, G. Schwaab, P. Wibault, B. Luboinski, F. Eschwege, T. Soussi, Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J. Natl. Cancer Inst. 88, 1228–1233 (1996)PubMedCrossRef
17.
Zurück zum Zitat R.J. Gao, H.Z. Bao, Q. Yang, Q. Cong, J.N. Song, L. Wang, The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters. Breast Cancer Res. Treat. 93, 111–115 (2005)PubMedCrossRef R.J. Gao, H.Z. Bao, Q. Yang, Q. Cong, J.N. Song, L. Wang, The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters. Breast Cancer Res. Treat. 93, 111–115 (2005)PubMedCrossRef
18.
Zurück zum Zitat N. Gandra, G. Abbineni, X. Qu, Y. Huai, L. Wang, C. Mao, Bacteriophage Bionanowire as a Carrier for Both Cancer-Targeting Peptides and Photosensitizers and its use in Selective Cancer Cell Killing by Photodynamic Therapy. Small 9, 215–221 (2013)PubMedCrossRefPubMedCentral N. Gandra, G. Abbineni, X. Qu, Y. Huai, L. Wang, C. Mao, Bacteriophage Bionanowire as a Carrier for Both Cancer-Targeting Peptides and Photosensitizers and its use in Selective Cancer Cell Killing by Photodynamic Therapy. Small 9, 215–221 (2013)PubMedCrossRefPubMedCentral
19.
Zurück zum Zitat D.H. Yu, J.H. Li, Y.C. Wang, J.G. Xu, P.T. Pan, L. Wang, Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12–5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients. Clin. Chim. Acta 412, 930–935 (2011)PubMedCrossRef D.H. Yu, J.H. Li, Y.C. Wang, J.G. Xu, P.T. Pan, L. Wang, Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12–5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients. Clin. Chim. Acta 412, 930–935 (2011)PubMedCrossRef
20.
Zurück zum Zitat K.S. Anderson, J. Wong, A. Vitonis, C.P. Crum, P.M. Sluss, J. Labaer, D. Cramer, p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 19, 859–868 (2010)PubMedCrossRefPubMedCentral K.S. Anderson, J. Wong, A. Vitonis, C.P. Crum, P.M. Sluss, J. Labaer, D. Cramer, p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 19, 859–868 (2010)PubMedCrossRefPubMedCentral
21.
Zurück zum Zitat S.A. McNeil, S.A. Halperin, J.M. Langley, B. Smith, A. Warren, G.P. Sharratt, D.M. Baxendale, M.A. Reddish, M.C. Hu, S.D. Stroop, J. Linden, L.F. Fries, P.E. Vink, J.B. Dale, Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin. Infect. Dis. 41, 1114–1122 (2005)PubMedCrossRef S.A. McNeil, S.A. Halperin, J.M. Langley, B. Smith, A. Warren, G.P. Sharratt, D.M. Baxendale, M.A. Reddish, M.C. Hu, S.D. Stroop, J. Linden, L.F. Fries, P.E. Vink, J.B. Dale, Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin. Infect. Dis. 41, 1114–1122 (2005)PubMedCrossRef
22.
Zurück zum Zitat C.J. Chapman, A. Murray, J.E. McElveen, U. Sahin, U. Luxemburger, Ö. Türeci, Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 63, 228–233 (2008)PubMedCrossRef C.J. Chapman, A. Murray, J.E. McElveen, U. Sahin, U. Luxemburger, Ö. Türeci, Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 63, 228–233 (2008)PubMedCrossRef
23.
Zurück zum Zitat J.Y. Zhang, C.A. Casiano, X.X. Peng, J.A. Koziol, E.K. Chan, E.M. Tan, Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol. Biomarkers Prev. 12, 136–143 (2003)PubMed J.Y. Zhang, C.A. Casiano, X.X. Peng, J.A. Koziol, E.K. Chan, E.M. Tan, Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol. Biomarkers Prev. 12, 136–143 (2003)PubMed
24.
Zurück zum Zitat S.J. Chatterjee, R. Datar, D. Youssefzadeh, B. George, P.J. Goebell, J.P. Stei, L. Young, S.R. Shi, C. Gee, S. Groshen, D.G. Skinner, R.J. Cote, Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J. Clin. Oncol. 22, 1007–1013 (2004)PubMedCrossRef S.J. Chatterjee, R. Datar, D. Youssefzadeh, B. George, P.J. Goebell, J.P. Stei, L. Young, S.R. Shi, C. Gee, S. Groshen, D.G. Skinner, R.J. Cote, Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J. Clin. Oncol. 22, 1007–1013 (2004)PubMedCrossRef
25.
Zurück zum Zitat R. Zigeuner, O. Tsybrovskyy, M. Ratschek, P. Rehak, K. Lipsky, C. Langner, Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology 63, 1079–1083 (2004)PubMedCrossRef R. Zigeuner, O. Tsybrovskyy, M. Ratschek, P. Rehak, K. Lipsky, C. Langner, Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology 63, 1079–1083 (2004)PubMedCrossRef
26.
Zurück zum Zitat R. Lubin, B. Schlichtholz, D. Bengoufa, G. Zalcman, J. Tredaniel, A. Hirsch, C. Caron de Fromentel, C. Preudhomme, P. Fenaux, G. Fournier, P. Mangin, P. Laurent-Puig, G. Pelletier, M. Schlumberger, F. Desgrandchamps, A. Le Duc, J.P. Peyrat, N. Janin, B. Bressac, T. Soussi, Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res. 53, 5872–5876 (1993)PubMed R. Lubin, B. Schlichtholz, D. Bengoufa, G. Zalcman, J. Tredaniel, A. Hirsch, C. Caron de Fromentel, C. Preudhomme, P. Fenaux, G. Fournier, P. Mangin, P. Laurent-Puig, G. Pelletier, M. Schlumberger, F. Desgrandchamps, A. Le Duc, J.P. Peyrat, N. Janin, B. Bressac, T. Soussi, Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res. 53, 5872–5876 (1993)PubMed
27.
Zurück zum Zitat B. Schlichtholz, J. Tredaniel, R. Lubin, G. Zalcman, A. Hirsch, T. Soussi, Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br. J. Cancer 69, 809–816 (1994)PubMedCrossRefPubMedCentral B. Schlichtholz, J. Tredaniel, R. Lubin, G. Zalcman, A. Hirsch, T. Soussi, Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br. J. Cancer 69, 809–816 (1994)PubMedCrossRefPubMedCentral
28.
Zurück zum Zitat F. Di Marzo Veronese, A.E. Willis, C. Boyer-Thompson, E. Appella, R.N. Perham, Structural mimicry and enhanced immunogenicity of peptide epitopes displayed on filamentous bacteriophage: the V3 loop of HIV-1 gp120. J. Mol. Biol. 243, 167–172 (1994) F. Di Marzo Veronese, A.E. Willis, C. Boyer-Thompson, E. Appella, R.N. Perham, Structural mimicry and enhanced immunogenicity of peptide epitopes displayed on filamentous bacteriophage: the V3 loop of HIV-1 gp120. J. Mol. Biol. 243, 167–172 (1994)
29.
Zurück zum Zitat L.L. Qiu, P.Y. Hua, L.L. Ye, Y.C. Wang, T. Qiu, H.Z. Bao, L. Wang, The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China. Cancer Detect. Prev. 31, 45–49 (2007)PubMedCrossRef L.L. Qiu, P.Y. Hua, L.L. Ye, Y.C. Wang, T. Qiu, H.Z. Bao, L. Wang, The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China. Cancer Detect. Prev. 31, 45–49 (2007)PubMedCrossRef
30.
Zurück zum Zitat T. Qiu, Q. Yang, X.R. Li, H. Yang, L.L. Qiu, L. Wang, Detection of serum anti-p53 antibodies from patients with ovarian cancer in China: correlation to clinical parameters. Cancer Invest. 25, 563–568 (2007)PubMedCrossRef T. Qiu, Q. Yang, X.R. Li, H. Yang, L.L. Qiu, L. Wang, Detection of serum anti-p53 antibodies from patients with ovarian cancer in China: correlation to clinical parameters. Cancer Invest. 25, 563–568 (2007)PubMedCrossRef
31.
Zurück zum Zitat X. Zheng, Y. Han, Y. Li, Y. Yu, X. Yun, X. Ren, M. Gao, Papillary Microcarcinoma of the Thyroid: Clinical Characteristics and BRAFV600E Mutational Status of 977 Cases. Ann. Surg. Oncol. 20, 2266–2273 (2013)PubMedCrossRef X. Zheng, Y. Han, Y. Li, Y. Yu, X. Yun, X. Ren, M. Gao, Papillary Microcarcinoma of the Thyroid: Clinical Characteristics and BRAFV600E Mutational Status of 977 Cases. Ann. Surg. Oncol. 20, 2266–2273 (2013)PubMedCrossRef
32.
Zurück zum Zitat M. Xing, W.H. Westra, R.P. Tufano, Y. Cohen, E. Rosenbaum, K.J. Rhoden, K.A. Carson, V. Vasko, A. Larin, G. Tallini, S. Tolaney, E.H. Holt, P. Hui, C.B. Umbricht, S. Basaria, M. Ewertz, A.P. Tufaro, J.A. Califano, M.D. Ringel, M.A. Zeiger, D. Sidransky, P.W. Ladenson, BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 90, 6373–6379 (2005)PubMedCrossRef M. Xing, W.H. Westra, R.P. Tufano, Y. Cohen, E. Rosenbaum, K.J. Rhoden, K.A. Carson, V. Vasko, A. Larin, G. Tallini, S. Tolaney, E.H. Holt, P. Hui, C.B. Umbricht, S. Basaria, M. Ewertz, A.P. Tufaro, J.A. Califano, M.D. Ringel, M.A. Zeiger, D. Sidransky, P.W. Ladenson, BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 90, 6373–6379 (2005)PubMedCrossRef
Metadaten
Titel
Detection of serum p53 antibodies from Chinese patients with papillary thyroid carcinoma using phage-SP-ELISA: correlation with clinical parameters
verfasst von
Pengtao Pan
Xiaoyi Han
Fangqian Li
Qingfeng Fu
Xiang Gao
Hui Sun
Li Wang
Publikationsdatum
01.11.2014
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2014
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0243-9

Weitere Artikel der Ausgabe 2/2014

Endocrine 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.